Intracellular efficacy of tumor-targeting group I intron-based trans-splicing ribozyme

Journal of Gene Medicine

Volumn 13, Issue 2, 2011, Pages 89-100

  Kwon, Byung Su ^a,b   Jeong, Jin Sook ^c   Won, You Sub ^a   Lee, Chang Ho ^a   Yoon, Kyung Sik ^d   Hyung Jung, Min ^b   Kim, In Hoo ^e   Lee, Seong Wook ^a  

^a Dankook University   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Dong A University College of Medicine   (South Korea)

^d Kyung Hee University   (South Korea)

^e National Cancer Center   (South Korea)

Author keywords

Cancer gene therapy; Group I intron; HTERT; trans splicing ribozyme; Tumor targeting

Indexed keywords

ADENOVIRUS VECTOR; MESSENGER RNA; RIBOZYME; TELOMERASE REVERSE TRANSCRIPTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEASIBILITY STUDY; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRON; MALE; MAMMAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANS SPLICING; TRANSCRIPTION REGULATION; TRANSGENE; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HEK293 CELLS; HT29 CELLS; HUMANS; INTRACELLULAR SPACE; INTRONS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; RNA, CATALYTIC; TELOMERASE; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; MAMMALIA;

EID: 79952672728     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1545     Document Type: Article

References (43)

1. Sullenger BA, Cech TR. Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing. Nature 1994; 371: 619-622.
2. Lan N, Howrey RP, Lee SW, Smith CA, Sullenger BA. Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors. Science 1998; 280: 1593-1596.
3. Puttaraju M, DiPasquale J, Baker CC, Mitchell LG, Garcia-Blanco MA. Messenger RNA repair and restoration of protein function by spliceosome-mediated RNA trans-splicing. Mol Ther 2001; 4: 105-114.
4. Liu X, Jiang Q, Mansfield SG, et al. Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat Biotechnol 2002; 20: 47-52.
5. Deidda G, Rossi N, Tocchini-Valentini GP. An archaeal endoribonuclease catalyzes cis- and trans- nonspliceosomal splicing in mouse cells. Nat Biotechnol 2003; 21: 1499-1504.
6. Di SG, Gastaldi S, Tocchini-Valentini GP. Cis- and trans-splicing of mRNAs mediated by tRNA sequences in eukaryotic cells. Proc Natl Acad Sci USA 2008; 105: 6864-6869.
7. Been MD, Cech TR. One binding site determines sequence specificity of Tetrahymena pre-rRNA self-splicing, trans-splicing, and RNA enzyme activity. Cell 1986; 47: 207-216.
8. Jones JT, Lee SW, Sullenger BA. Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells. Nat Med 1996; 2: 643-648.
9. Cech TR. Self-splicing of group I introns. Annu Rev Biochem 1990; 59: 543-568.
10. Phylactou LA. Repair of myotonic dystrophy protein kinase (DMPK) transcripts by trans-splicing ribozymes. Methods Mol Biol 2004; 252: 373-383.
11. Rogers CS, Vanoye CG, Sullenger BA, George AL. Functional repair of a mutant chloride channel using a trans-splicing ribozyme. J Clin Inves 2002; 110: 1783-1798.
12. Shin KS, Sullenger BA, Lee SW. Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. Mol Ther 2004; 10: 365-372.
13. Jung HS, Lee SW. Ribozyme-mediated selective killing of cancer cells expressing carcinoembryonic antigen RNA by targeted trans-splicing. Biochem Biophys Res Commun 2006; 349: 556-563.
14. Jung HS, Kwon BS, Lee SW. Tumor-specific gene delivery using RNA-targeting Tetrahymena group I intron. Biotechnol Lett 2005; 27: 567-574.
15. Kim A, Ban G, Song MS, Bae CD, Park J, Lee SW. Selective regression of cells expressing mouse cytoskeleton-associated protein 2 transcript by trans-splicing ribozyme. Oligonucleotides 2007; 17: 95-103.
16. Won YS, Lee SW. Targeted retardation of hepatocarcinoma cells by specific replacement of alpha-fetoprotein RNA. J Biotechnol 2007; 129: 614-619.
17. Kwon BS, Jung HS, Song MS, et al. Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript. Mol Ther 2005; 12: 824-834.
18. Song MS, Lee SW. Cancer-selective induction of cytotoxicity by tissue-specific expression of targeted trans-splicing ribozyme. FEBS Lett 2006; 580: 5033-5043.
19. Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999; 97: 527-538.
20. Hackett JA, Greider CW. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene 2002; 21: 619-626.
21. Hong SH, Jeong JS, Lee YJ, et al. In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells. Mol Ther 2008; 16: 74-80.
22. Jeong JS, Lee SW, Hong SH, et al. Antitumor effects of systemically delivered adenovirus harboring trans-splicing ribozyme in intrahepatic colon cancer mouse model. Clin Cancer Res 2008; 14: 281-290.
23. Song MS, Jeong JS, Ban G, et al. Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo. Cancer Gene Ther 2009; 16: 113-125.
24. Song MS, Jeong JS, Cho KS, Lee SW. Gene expression responses in vivo by human telomerase reverse transcriptase (hTERT)-targeting trans-splicing ribozyme. Exp Mol Med 2007; 39: 722-732.
25. Garcia-Blanco MA. Mending the message. Nat Biotechnol 2003; 21: 1448-1449.
26. Gooding LR. Regulation of TNF-mediated cell death and inflammation by human adenoviruses. Infect Agents Dis 1994; 3: 106-115.
27. Morral N, O'Neal WK, Rice K, et al. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther 2002; 13: 143-154.
28. Kobayashi K, Oka K, Forte T, et al. Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J Biol Chem 1996; 271: 6852-6860.
29. Kim NW, Platyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
30. Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997; 90: 785-795.
31. Masutomi K, Hahn WC. Telomerase and tumorigenesis. Cancer Lett 2003; 194: 163-172.
32. Smith LL, Coller HA, Roberts JM. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 2003; 5: 474-479.
33. Donello JE., Loeb JE, Hope TJ. Woodchuk hepatitis post-transcriptional regulatory element (WPRE). J Virol 1998; 72: 5085-5092.
34. Loeb JE, Cordier WS, Harris ME, Weitzman MD, Hope TJ. Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus poettranscriptionl regulatory element: implications for gene therapy. Hum Gene Ther 1999; 10: 2295-2305.
35. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuk hepatitis posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectos. J Virol 1999; 73: 2886-2892.
36. Klein R, Ruttkowski B, Knapp E, Salmons B, Günzburg W, Hohenadl C. WPRE-mediated enhancement of gene expression is promoter and cell line specific. Gene 2006; 372: 153-161.
37. Köhler U, Ayre BG, Goodman HM, Haseloff J. Trans-splicing ribozymes for targeted gene delivery. J Mol Biol 1999; 285: 1935-1950.
38. Lan N, Rooney BL, Lee SW, Howrey RP, Smith CA, Sullenger BA. Enhancing RNA repair efficiency by combining trans-splicing ribozymes that recognize different accessible sites on a target RNA. Mol Ther 2000; 2: 245-255.
39. Byun J, Lan N, Long M, Sullenger BA. Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes. RNA 2003; 9: 1254-1263.
40. Sullenger BA, Cech TR. Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 1993; 262: 1586-1589.
41. Xing Z, Whitton JL. Ribozymes which cleave arenavirus RNAs: identification of susceptible target sites and inhibition by target site secondary structure. J Virol 1992; 66: 1361-1369.
42. Sagan SM, Nashen N, Luebbert C, PeZacki JP. The efficacy of siRNAs against hepatitis C virus is a strongly influenced by structure and target site accessibility. Chem Biol 2010; 17: 515-527.
43. White LK, Wright WE, Shay JW. Telomerase inhibitors. Trends Biotechnol 2001; 19: 114-120.